Patients with metastatic colorectal cancer may continue to benefit from immunotherapy even after treatment is discontinued

Credit: Pixabay/CC0 Public Domain The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with immune checkpoint inhibitors (ICIs) had no disease progression for two years after stopping treatment, a new study reports. There is. Research is published in a diary cancer research communication. ICIs have proven effective against […]

Patients with metastatic colorectal cancer may continue to benefit from immunotherapy even after treatment is discontinued

Credit: Pixabay/CC0 Public Domain The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with immune checkpoint inhibitors (ICIs) had no disease progression for two years after stopping treatment, a new study reports. There is. Research is published in a diary cancer research communication. ICIs have proven effective against […]

RELATIVITY-123 MSS CRC unlikely to reach primary endpoint and will be discontinued

Other trials evaluating fixed-dose combinations of nivolumab and leratorimab as treatments for other tumor types will continue. The phase 3 RELATIVITY-123 trial (NCT05328908) tested nivolumab (Opdivo) and relatlimab (Opdurag) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who had disease progression after 1 to 4 days. ) is evaluating the effectiveness of combination […]